For cervical cancer screening
BD Diagnostics, a segment of BD (Becton, Dickinson and Company) has received clearance from the FDA to utilise its BD ProbeTec Chlamydia trachomatis (CT) Qx and BD ProbeTec Neisseria gonorrhoeae (GC) Qx amplified DNA assays with samples collected during women’s routine liquid-based Pap testing for cervical cancer screening.
The BD ProbeTec Qx amplified DNA assays are the first to receive FDA clearance for gynecological specimens collected and transported in the two leading types of liquid-based cytology (LBC) preservative media on the market.
These include the BD SurePath liquid-based Pap test, which uses detachable-head collection devices that help ensure 100 % of collected cells are sent to the laboratory for analysis. The company claims that the BD SurePath Pap test has FDA-approved claims for achieving the highest increase in HSIL+ disease detection and reducing unsatisfactory samples.
Wayne Brinster, vice president and general manager of women’s health and cancer at BD Diagnostics, said: “BD is leveraging technologies and expertise across the company to enhance disease detection and patient management in women’s health. Providing physicians and laboratories with the ability to test for chlamydia and gonorrhea while screening for cervical cancer increases their efficiency, and more importantly, improves the level of information they have to make important patient care decisions.”